IL144265A0 - Use of antibodies for the vaccination against cancer - Google Patents

Use of antibodies for the vaccination against cancer

Info

Publication number
IL144265A0
IL144265A0 IL14426500A IL14426500A IL144265A0 IL 144265 A0 IL144265 A0 IL 144265A0 IL 14426500 A IL14426500 A IL 14426500A IL 14426500 A IL14426500 A IL 14426500A IL 144265 A0 IL144265 A0 IL 144265A0
Authority
IL
Israel
Prior art keywords
against cancer
antibodies
vaccination against
prophylactically
medicament
Prior art date
Application number
IL14426500A
Other languages
English (en)
Original Assignee
Igeneon Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igeneon Gmbh filed Critical Igeneon Gmbh
Publication of IL144265A0 publication Critical patent/IL144265A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL14426500A 1999-01-13 2000-01-12 Use of antibodies for the vaccination against cancer IL144265A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH5199 1999-01-13
PCT/EP2000/000174 WO2000041722A1 (de) 1999-01-13 2000-01-12 Verwendung von antikörpern zur vakzinierung gegen krebs

Publications (1)

Publication Number Publication Date
IL144265A0 true IL144265A0 (en) 2002-05-23

Family

ID=4178206

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14426500A IL144265A0 (en) 1999-01-13 2000-01-12 Use of antibodies for the vaccination against cancer
IL144265A IL144265A (en) 1999-01-13 2001-07-11 Use of antibodies to vaccine against cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL144265A IL144265A (en) 1999-01-13 2001-07-11 Use of antibodies to vaccine against cancer

Country Status (28)

Country Link
US (3) US7691372B2 (sk)
EP (2) EP1140168B1 (sk)
JP (1) JP4774551B2 (sk)
KR (1) KR100771752B1 (sk)
CN (1) CN1188169C (sk)
AT (2) ATE286745T1 (sk)
AU (1) AU768515B2 (sk)
CA (1) CA2360382C (sk)
CZ (1) CZ302801B6 (sk)
DE (2) DE50000243D1 (sk)
DK (2) DK1230932T3 (sk)
EE (1) EE05474B1 (sk)
ES (2) ES2236375T3 (sk)
HK (1) HK1044487B (sk)
HR (1) HRP20010526A2 (sk)
HU (1) HU226150B1 (sk)
ID (1) ID30223A (sk)
IL (2) IL144265A0 (sk)
IS (1) IS5998A (sk)
MX (1) MXPA01007148A (sk)
NO (1) NO329917B1 (sk)
NZ (1) NZ512722A (sk)
PL (1) PL201533B1 (sk)
PT (2) PT1140168E (sk)
SI (2) SI1230932T1 (sk)
SK (1) SK286627B6 (sk)
TR (1) TR200102034T2 (sk)
WO (1) WO2000041722A1 (sk)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1140168E (pt) * 1999-01-13 2002-11-29 Igeneon Krebs Immuntherapie F Vacinacoes contra o cancro
AT410172B (de) * 2000-03-21 2003-02-25 Igeneon Gmbh Verfahren zur herstellung einer vakzineformulierung
AT502293B1 (de) * 2002-05-15 2008-03-15 Igeneon Krebs Immuntherapie Immunogener, monoklonaler antikörper
AT500647A1 (de) * 2002-05-21 2006-02-15 Igeneon Krebs Immuntherapie Verwendung eines impfstoffes
AT500650B1 (de) 2003-04-17 2009-11-15 Altropus Gmbh Immunogener rekombinanter antikörper
AT500651B9 (de) * 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
CA2573505C (en) 2004-07-14 2013-06-25 Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag N-glycosylated antibody
DE602004029455D1 (de) * 2004-07-20 2010-11-18 Altropus Gmbh Verwendung von Antikörpern in einer sehr geringen Dosis zur Impfung gegen Krebs
KR101205064B1 (ko) * 2005-04-26 2012-11-27 에자이 알앤드디 매니지먼트 가부시키가이샤 암 면역요법을 위한 조성물과 방법
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
AT504231A1 (de) 2006-10-03 2008-04-15 Hans Dr Loibner Prädiktive parameter
EP2898889B1 (en) 2007-12-07 2017-03-22 N.V. Nutricia Bifidobacterium for dust mite allergy
JP5764071B2 (ja) 2009-02-24 2015-08-12 エスバテック − ア ノバルティスカンパニー エルエルシー 細胞表面抗原のイムノバインダーを同定するための方法
US8887373B2 (en) 2012-02-24 2014-11-18 Covidien Lp Vessel sealing instrument with reduced thermal spread and method of manufacture therefor
US20140276968A1 (en) * 2013-03-14 2014-09-18 Ethicon, Inc. Applicator systems for surgical fasteners
WO2015013668A1 (en) * 2013-07-26 2015-01-29 Ke Zhang Anti-immunoglobulin e antibodies and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341281C (en) * 1986-07-09 2001-08-07 Hubert J.P. Schoemaker Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen
US5270202A (en) * 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5798100A (en) * 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
WO1997005597A1 (en) * 1995-07-31 1997-02-13 Litton Systems Canada Limited Flat panel pixel array incorporating photoconductive switches
EP0857176A1 (en) * 1995-10-25 1998-08-12 Centocor B.V. HUMAN EPITHELIAL ANTIGEN Ep-CAM DERIVED PEPTIDES AND THEIR USE
US6235280B1 (en) * 1996-04-12 2001-05-22 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
IL121041A0 (en) * 1997-06-09 1997-11-20 Yeda Res & Dev Immunogenic compositions for induction of anti-tumor immunity
US6274143B1 (en) * 1997-06-13 2001-08-14 Malaya Chatterjee Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
EP1085905B1 (en) * 1998-06-15 2010-09-08 Quest Pharmatech Inc. Immunotherapeutic composition and method for the treatment of prostate cancer
PT1140168E (pt) * 1999-01-13 2002-11-29 Igeneon Krebs Immuntherapie F Vacinacoes contra o cancro
AU2001261371A1 (en) * 2000-05-16 2001-11-26 New York University Anti-idiotypic antibody against fimh adhesin of uropathogenic type i-fimbriated escherichia coli, compositions containing same and method for using same

Also Published As

Publication number Publication date
ATE219687T1 (de) 2002-07-15
EP1230932A2 (de) 2002-08-14
PL364747A1 (en) 2004-12-13
ES2177509T3 (es) 2002-12-16
CZ302801B6 (cs) 2011-11-16
AU768515B2 (en) 2003-12-18
KR100771752B1 (ko) 2007-10-30
CN1344167A (zh) 2002-04-10
JP4774551B2 (ja) 2011-09-14
PT1140168E (pt) 2002-11-29
SI1140168T1 (en) 2002-10-31
KR20010101446A (ko) 2001-11-14
ATE286745T1 (de) 2005-01-15
NO20013093L (no) 2001-09-10
EE200100366A (et) 2002-10-15
US8444974B2 (en) 2013-05-21
US20070224202A1 (en) 2007-09-27
EP1230932A3 (de) 2003-11-26
HU226150B1 (en) 2008-05-28
SI1230932T1 (en) 2005-06-30
DK1140168T3 (da) 2002-09-30
ID30223A (id) 2001-11-15
EE05474B1 (et) 2011-10-17
MXPA01007148A (es) 2002-03-27
HK1044487A1 (en) 2002-10-25
DK1230932T3 (da) 2005-04-25
EP1140168A1 (de) 2001-10-10
NZ512722A (en) 2003-07-25
SK286627B6 (sk) 2009-02-05
PT1230932E (pt) 2005-04-29
DE50000243D1 (de) 2002-08-01
EP1230932B1 (de) 2005-01-12
US7691372B2 (en) 2010-04-06
WO2000041722A1 (de) 2000-07-20
US20100233178A1 (en) 2010-09-16
NO329917B1 (no) 2011-01-24
DE50009240D1 (de) 2005-02-17
SK9642001A3 (en) 2002-03-05
IL144265A (en) 2006-08-20
CN1188169C (zh) 2005-02-09
CA2360382C (en) 2011-05-24
AU2796400A (en) 2000-08-01
TR200102034T2 (tr) 2001-11-21
HK1044487B (zh) 2005-09-16
CZ20012581A3 (cs) 2002-01-16
IS5998A (is) 2001-07-10
US20120003232A1 (en) 2012-01-05
JP2002534481A (ja) 2002-10-15
NO20013093D0 (no) 2001-06-21
CA2360382A1 (en) 2000-07-20
HRP20010526A2 (en) 2002-08-31
EP1140168B1 (de) 2002-06-26
PL201533B1 (pl) 2009-04-30
ES2236375T3 (es) 2005-07-16
HUP0200527A2 (en) 2002-06-29

Similar Documents

Publication Publication Date Title
IL144265A0 (en) Use of antibodies for the vaccination against cancer
TR200001253T2 (tr) Tümöre özel antijenler
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
DE60134962D1 (de) Anti-ccr4 antikörper und fragmente davon
HUP0200537A2 (en) Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
AU2002355677A1 (en) Antigenic polypeptides
AU2002352394A1 (en) Focussed antibody technology
PL401886A1 (pl) Neutralizujace o wysokim powinowactwie izolowane ludzkie przeciwcialo anty-TNF-alfa, zastosowanie tego przeciwciala, krysztal zawierajacy ludzkie przeciwcialo anty-TNF-alfa i preparat zawierajacy ten krysztal
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
NZ514228A (en) Method of Expressing Antigens on the Surface of Antigen Presenting Cells by Photochemical Internalisation
WO2001068708A3 (en) Human and humanized fap-alpha-specific antibodies
EP1354896A4 (en) NEW MONOCLONAL ANTIBODY
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje
WO2000069915A3 (en) COMBINED APPROACH TO TREATMENT OF CANCER WITH hCG VACCINES
IL160029A0 (en) Receptor, the use thereof, and mouse antibodies
WO2004106379A8 (en) Immunotherapy of rectal cancer
MY143402A (en) Preparations used in the treatment and prophilaxis of mycobacterial infections
ZA200200730B (en) Human monoclonal antibodies to prostate specific membrane antigen.
AU2003209869A1 (en) Adjuvant system for the production of antibodies, vaccine and use
AU2002307822A1 (en) Generation of monoclonal antibodies to poorly immunogenic antigens expressed or carried by eukaryotic cells, use of monoclonal antibodies for therapeutical, diagnostic or vaccine applications
TH58554B (th) วัคซีนที่ถูกยับยั้งฤทธิ์ต่อแคลิซิไวโรซิสของสัตว์จำพวกแมว

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed